Anomaly Detection in RFID Networks

Available security standards for RFID networks (e.g. ISO/IEC 29167) are designed to secure individual tag-reader sessions and do not protect against active attacks that could also compromise the system as a whole (e.g. tag cloning or replay attacks). Proper traffic characterization models of the communication within an RFID network can lead to better understanding of operation under “normal” system state conditions and can consequently help identify security breaches not addressed by current standards. This study of RFID traffic characterization considers two piecewise-constant data smoothing techniques, namely Bayesian blocks and Knuth’s algorithms, over time-tagged events and compares them in the context of rate-based anomaly detection. This was accomplished using data from experimental RFID readings and comparing (1) the event counts versus time if using the smoothed curves versus empirical histograms of the raw data and (2) the threshold-dependent alert-rates based on inter-arrival times obtained if using the smoothed curves versus that of the raw data itself. Results indicate that both algorithms adequately model RFID traffic in which inter-event time statistics are stationary but that Bayesian blocks become superior for traffic in which such statistics experience abrupt changes

Advanced 3D Electrospinning “Xspin” System: Fabrication of Bifiber Floating Oral Pharmaceutical Scaffolds for Controlled Drug Delivery

Electrospinning has become a widely used and efficient method for manufacturing nanofibers from diverse polymers. This study introduces an advanced electrospinning technique, Xspin - a multi-functional 3D printing platform coupled with electrospinning system, integrating a customised 3D printhead, MaGIC - Multi-channeled and Guided Inner Controlling printheads. The Xspin system represents a cutting-edge fusion of electrospinning and 3D printing technologies within the realm of pharmaceutical sciences and biomaterials. This innovative platform excels in the production of novel fiber with various materials and allows for the creation of highly customized fiber structures, a capability hitherto unattainable through conventional electrospinning methodologies. By integrating the benefits of electrospinning with the precision of 3D printing, the Xspin system offers enhanced control over the scaffold morphology and drug release kinetics. Herein, we fabricated a model floating pharmaceutical dosage for the dual delivery of curcumin and ritonavir and thoroughly characterized the product. Fourier transform infrared (FTIR) spectroscopy demonstrated that curcumin chemically reacted with the polymer during the Xspin process. Thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) confirmed the solid-state properties of the active pharmaceutical ingredient after Xspin processing. Scanning electron microscopy (SEM) revealed the surface morphology of the Xspin-produced fibers, confirming the presence of the bifiber structure. To optimize the quality and diameter control of the electrospun fibers, a design of experiment (DoE) approach based on quality by design (QbD) principles was utilized. The bifibers expanded to approximately 10–11 times their original size after freeze-drying and effectively entrapped 87% curcumin and 84% ritonavir. In vitro release studies demonstrated that the Xspin system released 35% more ritonavir than traditional pharmaceutical pills in 2 h, with curcumin showing complete release in pH 1.2 in 5 min, simulating stomach media. Furthermore, the absorption rate of curcumin was controlled by the characteristics of the linked polymer, which enables both drugs to be absorbed at the desired time. Additionally, multivariate statistical analyses (ANOVA, pareto chart, etc.) were conducted to gain better insights and understanding of the results such as discern statistical differences among the studied groups. Overall, the Xspin system shows significant potential for manufacturing nanofiber pharmaceutical dosages with precise drug release capabilities, offering new opportunities for controlled drug delivery applications